Aclarion, Inc. Warrant 2022- on Aclarion ACONW 深 滬
交易中 01-30 10:32:21 美东时间
0.0332
-0.002
-6.48%
華盛通- 最 高0.0332
- 今 開0.0332
- 成交量 201股
- 最 低 0.0332
- 昨 收 0.0355
- 總市值 0
- 52周最高 0.2333
- 市盈率 靜 --
- 換手率 Infinity.00%
- 52周最低 0.0214
- 委 比 67.64%
- 總股本 --
- 歷史最高 1.00
- 量 比 5.63
- 振 幅 0.00%
- 歷史最低 0.0051
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data
Northwestern Medicine and Scripps Health have joined two previously announced sites in achieving the patient enrollment milestone for Aclarion's pivotal CLARITY trial, aiming to improve outcomes for chronic low back pain surgery. With four sites now enrolling patients, seven leading U.S. spine centers have completed the regulatory and operational requirements to participate. The trial is designed to evaluate whether incorporating the Nociscan pla...
01-06 11:00
Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.
Aclarion, Inc. has appointed Jason Brosniak as Commercial Director for the Eastern U.S. With over 20 years of experience in MedTech, Brosniak brings expertise in launching breakthrough technologies across spine, neurosurgery, and pain management. His appointment aims to strengthen Aclarion’s commercial execution as it expands Nociscan’s adoption and payer engagement in the densely populated Eastern U.S. Nociscan, a first-of-its-kind SaaS platform...
2025-12-02 13:00
Aclarion Begins Pivotal CLARITY Trial To Test Nociscan's Impact On Chronic Low Back Pain Surgeries
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the
2025-09-25 18:05
Aclarion Launches Major US Trial to Test AI Tool That Could Improve Spine Surgery for Chronic Back Pain
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the
2025-06-25 18:02
First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial
Aclarion, Inc. announced the initiation of the CLARITY trial, enrolling the first patient at the Texas Back Institute. This randomized clinical trial evaluates Nociscan's ability to improve surgical outcomes for chronic low back pain using MR Spectroscopy and AI. Aiming to become the gold standard, Nociscan identifies pain sources non-invasively.中期结果预计在2026年第二季度公布。The trial involves 300 patients across multiple sites, focusing on discogenic low b...
2025-06-25 10:00
Aclarion Adds USC's Keck Medical Center to Spine Pain Study, Joining Johns Hopkins, Northwestern
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the
2025-05-20 18:05
Aclarion Signs Commercial Deal with Scripps Health to Expand Nociscan for Spine Care
Aclarion, Inc.,("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify
2025-03-03 19:01
Aclarion Announces Pricing Of $14.4M Public Offering Of Common Stock and Warrants
January 15, 2025 (NEWMEDIAWIRE- Opens in new window) - Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented
2025-01-15 22:30
Aclarion to Present at August 20th Virtual Investor Summit Microcap Event
BROOMFIELD, CO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc. ("Aclarion" or...
2024-08-15 21:48
Aclarion's Nociscan Gains Second Payer Coverage in UK, Enhancing Chronic Low Back Pain Diagnosis
Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help
2024-07-09 19:03
